The U.S. government projects Leqembi, the newly approved Alzheimer’s therapy from Biogen (NASDAQ:BIIB), will cost $3.5B ...

Sage Therapeutics said on Wednesday it would stop working on its experimental drug for Parkinson's disease after the ...

Deep-pocketed investors have adopted a bearish approach towards Biogen BIIB, and it's something market players shouldn't ...

After getting a fat check worth $30.5 million for joining Biogen as the CEO in late 2022, Chris Viehbacher saw his 2023 pay drop to $4.1 million as the Big Biotech continues to struggle. | After ...

Biogen Inc. ( NASDAQ:BIIB) is an American biopharmaceutical company specializing in the development and commercialization of ...

Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform' ...

If you thought that Eli Lilly's donanemab could ensure a smooth regulatory flight in the slipstream of Eisai and Biogen, the FDA has other ideas. | Fervent FDA watchers may note that the FDA typically ...

“(Then) John came available opportunistically recently.” Cox said he first came to Boston during his 14-year tenure at Biogen Inc. (NASDAQ: BIIB). During his time at Biogen, Cox served as ...

The series, Rethinking Alzheimer’s Disease, will focus on steps listeners can take to lower their risk of developing the ...

Data integrity – start-to-finish transparency, accuracy, consistency, relevance and lack of bias – is critical to the success of gen AI.

In terms of liquidity and interest, the mean open interest for Biogen options trades today is 95.5 with a total volume of 647 ...